+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1876467-74-1
1876467-74-1,MFCD31561442
Catalog No.:AA01DDQN

1876467-74-1 | (R)-3-Methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥98%
in stock  
$129.00   $90.00
- +
10mg
≥98%
in stock  
$230.00   $161.00
- +
100mg
98%
in stock  
$336.00   $235.00
- +
250mg
98%
in stock  
$407.00   $285.00
- +
1g
98%
in stock  
$1,499.00   $1,049.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA01DDQN
Chemical Name:
(R)-3-Methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine
CAS Number:
1876467-74-1
Molecular Formula:
C20H21N7O
Molecular Weight:
375.4270
MDL Number:
MFCD31561442
SMILES:
C[C@@H]1COCCN1c1cc(c2ccnn2C)c2c(n1)c(ncc2)c1n[nH]cc1
Properties
Computed Properties
 
Complexity:
537  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
3  
XLogP3:
1.6  

Downstream Synthesis Route

[1]CurrentPatentAssignee:POLINUTRIALIMENTOSSA;BAYERAG-WO2016/20320,2016,A1

[2]Lücking,Ulrich;Wortmann,Lars;Wengner,AntjeM.;Lefranc,Julien;Lienau,Philip;Briem,Hans;Siemeister,Gerhard;Bömer,Ulf;Denner,Karsten;Schäfer,Martina;Koppitz,Marcus;Eis,Knut;Bartels,Florian;Bader,Benjamin;Bone,Wilhelm;Moosmayer,Dieter;Holton,SimonJ.;Eberspächer,Uwe;Grudzinska-Goebel,Joanna;Schatz,Christoph;Deeg,Gesa;Mumberg,Dominik;VonNussbaum,Franz[JournalofMedicinalChemistry,2020,vol.63,#13,p.7293-7325]

[1]CurrentPatentAssignee:POLINUTRIALIMENTOSSA;BAYERAG-WO2016/20320,2016,A1

[2]Lücking,Ulrich;Wortmann,Lars;Wengner,AntjeM.;Lefranc,Julien;Lienau,Philip;Briem,Hans;Siemeister,Gerhard;Bömer,Ulf;Denner,Karsten;Schäfer,Martina;Koppitz,Marcus;Eis,Knut;Bartels,Florian;Bader,Benjamin;Bone,Wilhelm;Moosmayer,Dieter;Holton,SimonJ.;Eberspächer,Uwe;Grudzinska-Goebel,Joanna;Schatz,Christoph;Deeg,Gesa;Mumberg,Dominik;VonNussbaum,Franz[JournalofMedicinalChemistry,2020,vol.63,#13,p.7293-7325]

[1]CurrentPatentAssignee:POLINUTRIALIMENTOSSA;BAYERAG-WO2016/20320,2016,A1

[1]CurrentPatentAssignee:POLINUTRIALIMENTOSSA;BAYERAG-WO2016/20320,2016,A1

[2]Lücking,Ulrich;Wortmann,Lars;Wengner,AntjeM.;Lefranc,Julien;Lienau,Philip;Briem,Hans;Siemeister,Gerhard;Bömer,Ulf;Denner,Karsten;Schäfer,Martina;Koppitz,Marcus;Eis,Knut;Bartels,Florian;Bader,Benjamin;Bone,Wilhelm;Moosmayer,Dieter;Holton,SimonJ.;Eberspächer,Uwe;Grudzinska-Goebel,Joanna;Schatz,Christoph;Deeg,Gesa;Mumberg,Dominik;VonNussbaum,Franz[JournalofMedicinalChemistry,2020,vol.63,#13,p.7293-7325]

[3]CurrentPatentAssignee:BAYERAG-WO2020/39025,2020,A1

[4]CurrentPatentAssignee:BAYERAG-WO2020/39025,2020,A1

[1]CurrentPatentAssignee:POLINUTRIALIMENTOSSA;BAYERAG-WO2016/20320,2016,A1

[2]Lücking,Ulrich;Wortmann,Lars;Wengner,AntjeM.;Lefranc,Julien;Lienau,Philip;Briem,Hans;Siemeister,Gerhard;Bömer,Ulf;Denner,Karsten;Schäfer,Martina;Koppitz,Marcus;Eis,Knut;Bartels,Florian;Bader,Benjamin;Bone,Wilhelm;Moosmayer,Dieter;Holton,SimonJ.;Eberspächer,Uwe;Grudzinska-Goebel,Joanna;Schatz,Christoph;Deeg,Gesa;Mumberg,Dominik;VonNussbaum,Franz[JournalofMedicinalChemistry,2020,vol.63,#13,p.7293-7325]

Literature

Title: Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.

Title: Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement

Title: Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63(13):7293-7325.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1876467-74-1
Building Blocks
More >
Tags:1876467-74-1 Molecular Formula|1876467-74-1 MDL|1876467-74-1 SMILES|1876467-74-1 (R)-3-Methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine